Functional lung MRI for regional treatment monitoring of patients with cystic fibrosis

Functional lung MRI for regional treatment monitoring of patients with cystic fibrosis: a case-control study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN11682934

Enrollment

Registered

2017-06-19

Start date

2013-02-21

Completion date

Unknown

Last updated

2017-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic fibrosis Nutritional, Metabolic, Endocrine Cystic fibrosis

Interventions

All patients receive a pre-treatment MRI scan, lung function test, and oxygen saturation measurements during their outpatient day visit. Then they receive a treatment with inhaled hypertonic saline (7

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with cystic fibrosis 2. Aged between 12 and 24 3. Patients must be in a clinically stable condition with a confirmed diagnosis of cystic fibrosis 4. The forced expiratory volume in one second (FEV1) must have a minimum volume of >40 percent predicted for age and gender at the pre MRI lung function test

Exclusion criteria

Exclusion criteria: 1. Pregnant or breastfeeding women 2. Cigarette smokers 3. Patients with hypertonic saline treatment (HST) within the last 7 days 4. Contraindications to MRI or contrast media (allergy to MRI or CT contrast media, GFR< 30 mL/min/1.73 m2) 5. No (patient or parental) consent to participate

Design outcomes

Primary

Measure	Time frame
Functional lung MRI parameters at baseline and 2h after treatment	—

Secondary

Measure	Time frame
No secondary outcome measures	—

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026